{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:17:05Z","timestamp":1788369425215,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2025JJ40100"],"award-info":[{"award-number":["2025JJ40100"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2024JJ6728"],"award-info":[{"award-number":["2024JJ6728"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2025JJ70052"],"award-info":[{"award-number":["2025JJ70052"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017695","name":"Health Commission of Hunan Province","doi-asserted-by":"publisher","award":["Z2023100"],"award-info":[{"award-number":["Z2023100"]}],"id":[{"id":"10.13039\/100017695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103221"],"award-info":[{"award-number":["82103221"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06468-5","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T05:18:45Z","timestamp":1744953525000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["GPX2 inhibition enhances antitumor efficacy of lenvatinib via promoting immunogenic cell death in hepatocellular carcinoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Yingzheng","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingbin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2142-7030","authenticated-orcid":false,"given":"Wenliang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"key":"6468_CR1","first-page":"221","volume":"46","author":"RS Zheng","year":"2024","unstructured":"Zheng RS, Chen R, Han BF, Wang SM, Li L, Sun KX, Zeng HM, Wei WW, He J. Cancer incidence and mortality in China, 2022. Zhonghua Zhong Liu Za Zhi. 2024;46:221\u201331.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"6468_CR2","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/cac2.12025","volume":"40","author":"M Cao","year":"2020","unstructured":"Cao M, Li H, Sun D, Chen W. Cancer burden of major cancers in China: a need for sustainable actions. Cancer Commun (Lond). 2020;40:205\u201310.","journal-title":"Cancer Commun (Lond)"},{"key":"6468_CR3","doi-asserted-by":"publisher","first-page":"e555","DOI":"10.1016\/S2214-109X(18)30127-X","volume":"6","author":"H Zeng","year":"2018","unstructured":"Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, Xia C, Sun K, Yang Z, Li H, et al. Changing cancer survival in China during 2003\u201315: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6:e555\u201367.","journal-title":"Lancet Glob Health"},{"key":"6468_CR4","doi-asserted-by":"publisher","first-page":"308","DOI":"10.2478\/jtim-2022-0068","volume":"10","author":"K Moller","year":"2022","unstructured":"Moller K, Safai Zadeh E, Gorg C, Dong Y, Cui X, Lim A, de Molo C, Serra C, Martin Algibez A, Berzigotti A, et al. Focal liver lesions other than hepatocellular carcinoma in cirrhosis: diagnostic challenges. J Transl Int Med. 2022;10:308\u201327.","journal-title":"J Transl Int Med"},{"key":"6468_CR5","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"6468_CR6","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402:1133\u201346.","journal-title":"Lancet"},{"key":"6468_CR7","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"6468_CR8","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol. 2021;22:977\u201390.","journal-title":"Lancet Oncol"},{"key":"6468_CR9","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1399\u2013410.","journal-title":"Lancet Oncol"},{"key":"6468_CR10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","volume":"23","author":"G Kroemer","year":"2022","unstructured":"Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol. 2022;23:487\u2013500.","journal-title":"Nat Immunol"},{"key":"6468_CR11","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1084\/jem.20050915","volume":"202","author":"N Casares","year":"2005","unstructured":"Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202:1691\u2013701.","journal-title":"J Exp Med"},{"key":"6468_CR12","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/onc.2009.356","volume":"29","author":"A Tesniere","year":"2010","unstructured":"Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29:482\u201391.","journal-title":"Oncogene"},{"key":"6468_CR13","doi-asserted-by":"publisher","first-page":"100045","DOI":"10.1016\/j.ntm.2024.100045","volume":"3","author":"G Xu","year":"2024","unstructured":"Xu G, Li J, Zhang S, Cai J, Deng X, Wang Y, Pei P. Two-dimensional nano-biomaterials in regulating the tumor microenvironment for immunotherapy. Nano TransMed. 2024;3:100045.","journal-title":"Nano TransMed"},{"key":"6468_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51\u201372.","journal-title":"Annu Rev Immunol"},{"key":"6468_CR15","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1111\/cas.13806","volume":"109","author":"T Kimura","year":"2018","unstructured":"Kimura T, Kato Y, Ozawa Y, Kodama K, Ito J, Ichikawa K, Yamada K, Hori Y, Tabata K, Takase K, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci. 2018;109:3993\u20134002.","journal-title":"Cancer Sci"},{"key":"6468_CR16","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1002\/hep.32023","volume":"74","author":"L Torrens","year":"2021","unstructured":"Torrens L, Montironi C, Puigveh\u00ed M, Mesropian A, Leslie J, Haber PK, Maeda M, Balaseviciute U, Willoughby CE, Abril-Fornaguera J, et al. Immunomodulatory effects of lenvatinib plus anti-programmed cell death protein 1 in mice and rationale for patient enrichment in hepatocellular carcinoma. Hepatology. 2021;74:2652\u201369.","journal-title":"Hepatology"},{"key":"6468_CR17","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/hep.31921","volume":"74","author":"C Yi","year":"2021","unstructured":"Yi C, Chen L, Lin Z, Liu L, Shao W, Zhang R, Lin J, Zhang J, Zhu W, Jia H, et al. Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC. Hepatology. 2021;74:2544\u201360.","journal-title":"Hepatology"},{"key":"6468_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2478\/jtim-2023-0136","volume":"12","author":"J Zhang","year":"2024","unstructured":"Zhang J, Yin Z, Liang Z, Bai Y, Zhang T, Yang J, Li X, Xue L. Impacts of cryopreservation on phenotype and functionality of mononuclear cells in peripheral blood and ascites. J Transl Int Med. 2024;12:51\u201363.","journal-title":"J Transl Int Med"},{"key":"6468_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jare.2022.03.012","volume":"44","author":"W Tan","year":"2023","unstructured":"Tan W, Zhang K, Chen X, Yang L, Zhu S, Wei Y, Xie Z, Chen Y, Shang C. GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinoma. J Adv Res. 2023;44:173\u201383.","journal-title":"J Adv Res"},{"key":"6468_CR20","doi-asserted-by":"publisher","first-page":"4816","DOI":"10.1021\/acsnano.0c00708","volume":"14","author":"Z Yu","year":"2020","unstructured":"Yu Z, Guo J, Hu M, Gao Y, Huang L. Icaritin exacerbates mitophagy and synergizes with doxorubicin to induce immunogenic cell death in hepatocellular carcinoma. ACS Nano. 2020;14:4816\u201328.","journal-title":"ACS Nano"},{"key":"6468_CR21","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s13402-020-00552-2","volume":"43","author":"H Zhu","year":"2020","unstructured":"Zhu H, Shan Y, Ge K, Lu J, Kong W, Jia C. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy. Cell Oncol (Dordr). 2020;43:1203\u201314.","journal-title":"Cell Oncol (Dordr)"},{"key":"6468_CR22","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/2643-3230.BCD-21-0047","volume":"2","author":"A Gulla","year":"2021","unstructured":"Gulla A, Morelli E, Samur MK, Botta C, Hideshima T, Bianchi G, Fulciniti M, Malvestiti S, Prabhala RH, Talluri S, et al. Bortezomib induces anti-multiple myeloma immune response mediated by cGAS\/STING pathway activation. Blood Cancer Discov. 2021;2:468\u201383.","journal-title":"Blood Cancer Discov"},{"key":"6468_CR23","doi-asserted-by":"publisher","first-page":"102351","DOI":"10.1016\/j.redox.2022.102351","volume":"54","author":"Z Xu","year":"2022","unstructured":"Xu Z, Xu J, Sun S, Lin W, Li Y, Lu Q, Li F, Yang Z, Lu Y, Liu W. Mecheliolide elicits ROS-mediated ERS driven immunogenic cell death in hepatocellular carcinoma. Redox Biol. 2022;54:102351.","journal-title":"Redox Biol"},{"key":"6468_CR24","doi-asserted-by":"publisher","first-page":"101047","DOI":"10.1016\/j.redox.2018.11.005","volume":"25","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Zhang L, Zhou L, Lei Y, Zhang Y, Huang C. Redox signaling and unfolded protein response coordinate cell fate decisions under ER stress. Redox Biol. 2019;25:101047.","journal-title":"Redox Biol"},{"key":"6468_CR25","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/s41467-020-15067-5","volume":"11","author":"M Mahameed","year":"2020","unstructured":"Mahameed M, Boukeileh S, Obiedat A, Darawshi O, Dipta P, Rimon A, McLennan G, Fassler R, Reichmann D, Karni R, et al. Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy. Nat Commun. 2020;11:1304.","journal-title":"Nat Commun"},{"key":"6468_CR26","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","volume":"5","author":"A Huang","year":"2020","unstructured":"Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5:146.","journal-title":"Signal Transduct Target Ther"},{"key":"6468_CR27","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","volume":"595","author":"H Jin","year":"2021","unstructured":"Jin H, Shi Y, Lv Y, Yuan S, Ramirez CFA, Lieftink C, Wang L, Wang S, Wang C, Dias MH, et al. EGFR activation limits the response of liver cancer to lenvatinib. Nature. 2021;595:730\u20134.","journal-title":"Nature"},{"key":"6468_CR28","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1158\/0008-5472.CAN-21-4140","volume":"82","author":"B Hu","year":"2022","unstructured":"Hu B, Zou T, Qin W, Shen X, Su Y, Li J, Chen Y, Zhang Z, Sun H, Zheng Y, et al. Inhibition of EGFR overcomes acquired lenvatinib resistance driven by STAT3-ABCB1 signaling in hepatocellular carcinoma. Cancer Res. 2022;82:3845\u201357.","journal-title":"Cancer Res"},{"key":"6468_CR29","doi-asserted-by":"publisher","DOI":"10.15212\/bioi-2021-0011","author":"X Shi","year":"2022","unstructured":"Shi X, Zhang X, Zhang X, Guo H, Wang S. The integration of reactive oxygen species generation and prodrug activation for cancer therapy. BIO Integr. 2022. https:\/\/doi.org\/10.15212\/bioi-2021-0011.","journal-title":"BIO Integr"},{"key":"6468_CR30","doi-asserted-by":"publisher","first-page":"155317","DOI":"10.1016\/j.phymed.2023.155317","volume":"128","author":"X Chen","year":"2024","unstructured":"Chen X, Zhu N, Wu Y, Zhang Y, Zhang Y, Jin K, Zhou Z, Chen G, Wang J. Withaferin A, a natural thioredoxin reductase 1 (TrxR1) inhibitor, synergistically enhances the antitumor efficacy of sorafenib through ROS-mediated ER stress and DNA damage in hepatocellular carcinoma cells. Phytomedicine. 2024;128:155317.","journal-title":"Phytomedicine"},{"key":"6468_CR31","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41392-021-00594-4","volume":"6","author":"J Xu","year":"2021","unstructured":"Xu J, Ji L, Ruan Y, Wan Z, Lin Z, Xia S, Tao L, Zheng J, Cai L, Wang Y, et al. UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1\u03b2 in hepatocellular carcinoma. Signal Transduct Target Ther. 2021;6:190.","journal-title":"Signal Transduct Target Ther"},{"key":"6468_CR32","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1080\/17474086.2024.2391102","volume":"17","author":"Z Eftekhar","year":"2024","unstructured":"Eftekhar Z, Aghaei M, Saki N. DNA damage repair in megakaryopoiesis: molecular and clinical aspects. Expert Rev Hematol. 2024;17:705\u201312.","journal-title":"Expert Rev Hematol"},{"key":"6468_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-024-01310-y","author":"X Wang","year":"2024","unstructured":"Wang X, Li QQ, Tang YX, Li Y, Zhang L, Xu FF, Fu XL, Ye K, Ma JQ, Guo SM, et al. Oncoprotein LAMTOR5-mediated CHOP silence via DNA hypermethylation and miR-182\/miR-769 in promotion of liver cancer growth. Acta Pharmacol Sin. 2024. https:\/\/doi.org\/10.1038\/s41401-024-01310-y.","journal-title":"Acta Pharmacol Sin"},{"key":"6468_CR34","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s41419-024-06685-8","volume":"15","author":"X Li","year":"2024","unstructured":"Li X, Pan YF, Chen YB, Wan QQ, Lin YK, Shang TY, Xu MY, Jiang TY, Pei MM, Tan YX, et al. Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma. Cell Death Dis. 2024;15:300.","journal-title":"Cell Death Dis"},{"key":"6468_CR35","doi-asserted-by":"publisher","DOI":"10.15212\/bioi-2024-0012","author":"Z Guo","year":"2024","unstructured":"Guo Z, Saw PE, Jon S. Non-invasive physical stimulation to modulate the tumor microenvironment: unveiling a new frontier in cancer therapy. BIO Integr. 2024. https:\/\/doi.org\/10.15212\/bioi-2024-0012.","journal-title":"BIO Integr"},{"key":"6468_CR36","doi-asserted-by":"publisher","first-page":"84","DOI":"10.61186\/ijbc.16.2.84","volume":"16","author":"SA Aghapour","year":"2024","unstructured":"Aghapour SA, Torabizadeh M, Bahreiny SS, Saki N, Jalali Far MA, Yousefi-Avarvand A, Dost Mohammad Ghasemi K, Aghaei M, Abolhasani MM, Sharifani MS, et al. Investigating the dynamic interplay between cellular immunity and tumor cells in the fight against cancer: an updated comprehensive review. Iran J Blood Cancer. 2024;16:84\u2013101.","journal-title":"Iran J Blood Cancer"},{"key":"6468_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002305","author":"H Deng","year":"2021","unstructured":"Deng H, Kan A, Lyu N, He M, Huang X, Qiao S, Li S, Lu W, Xie Q, Chen H, et al. Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2020-002305.","journal-title":"J Immunother Cancer"},{"key":"6468_CR38","doi-asserted-by":"publisher","first-page":"e70008","DOI":"10.1002\/hsr2.70008","volume":"7","author":"M Aghaei","year":"2024","unstructured":"Aghaei M, Khademi R, Bahreiny SS, Saki N. The need to establish and recognize the field of clinical laboratory science (CLS) as an essential field in advancing clinical goals. Health Sci Rep. 2024;7:e70008.","journal-title":"Health Sci Rep"},{"key":"6468_CR39","doi-asserted-by":"publisher","first-page":"100036","DOI":"10.1016\/j.ntm.2024.100036","volume":"3","author":"P Ma","year":"2024","unstructured":"Ma P, Wang G, Men K, Li C, Gao N, Li L. Advances in clinical application of nanoparticle-based therapy for cancer treatment: a systematic review. Nano TransMed. 2024;3:100036.","journal-title":"Nano TransMed"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06468-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06468-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06468-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T05:18:46Z","timestamp":1744953526000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06468-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6468"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06468-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]},"assertion":[{"value":"13 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experiments received approval from the Animal Ethics Committee at Sun Yat-sen University (SYSU-IACUC-2024-002020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"456"}}